Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of progression of very early symptoms in axial spondyloarthritis with etanercept
2009-015515-40Phase 2Active
- Sponsor
- Wyeth
- Start
- Sep 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in axial spondyloarthritis (axSpA) and ankylosing spondylitis (AS) comparing Etanercept with Placebo (2 arms). Primary endpoint: Decrease of inflammation on MRI. Started Sep 2009; status: active.
02
Drugs
etanercept
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2009-015515-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015515-40.